Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3

被引：0

作者：

Zangari, Maurizio ^{[1
]}

Stein, Caleb K. ^{[1
]}

Yaccoby, Shmuel ^{[1
]}

Yoon, Donghoon ^{[1
]}

Heuck, Christoph ^{[1
]}

Jethava, Yogesh ^{[1
]}

Johann, Donald ^{[1
]}

Khan, Rashid Z. ^{[1
]}

Papanikolaou, Xenofon ^{[1
]}

van Rhee, Frits ^{[1
]}

Davies, Faith E. ^{[1
]}

Morgan, Gareth J. ^{[1
]}

Barlogie, Bart ^{[1
]}

机构：

[1] Univ Arkansas Med Sci, Little Rock, AR 72205 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 14 条

[1] Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
Danziger, Samuel A.
McConnell, Mark
Gockley, Jake
Young, Mary H.
Rosenthal, Adam
Schmitz, Frank
Reiss, David J.
Farmer, Phil
Alapat, Daisy, V
Singh, Amrit
Ashby, Cody
Bauer, Michael
Ren, Yan
Smith, Kelsie
Couto, Suzana S.
van Rhee, Frits
Davies, Faith
Zangari, Maurizio
Petty, Nathan
Orlowski, Robert Z.
Dhodapkar, Madhav, V
Copeland, Wilbert B.
Fox, Brian
Hoering, Antje
Fitch, Alison
Newhall, Katie
Barlogie, Bart
Trotter, Matthew W. B.
Hershberg, Robert M.
Walker, Brian A.
Dervan, Andrew P.
Ratushny, Alexander, V
Morgan, Gareth J.
PLOS MEDICINE, 2020, 17 (11)
[2] Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study
Huang, Shang-Yi
Lin, Hsiu-Hsia
Yao, Ming
Tang, Jih-Luh
Wu, Shang-Ju
Hou, Hsin-An
Chou, Wen-Chien
Chou, Sheng-Chieh
Hsu, Szu-Chun
Ko, Bor-Sheng
Lu, Hsiao-Yun
Tsay, Woei
Tien, Hwei-Fang
PLOS ONE, 2015, 10 (09):
[3] Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials (vol 17, e1003323, 2020)
Danziger, Samuel A.
McConnell, Mark
Gockley, Jake
Young, Mary H.
Rosenthal, Adam
Schmitz, Frank
Reiss, David J.
Farmer, Phil
Alapat, Daisy V.
Singh, Amrit
Ashby, Cody
Bauer, Michael
Ren, Yan
Smith, Kelsie
Couto, Suzana S.
van Rhee, Frits
Davies, Faith
Zangari, Maurizio
Petty, Nathan
Orlowski, Robert Z.
Dhodapkar, Madhav, V
Copeland, Wilbert B.
Fox, Brian
Hoering, Antje
Fitch, Alison
Newhall, Katie
Barlogie, Bart
Trotter, Matthew W. B.
Hershberg, Robert M.
Walker, Brian A.
Dervan, Andrew P.
Ratushny, Alexander, V
Morgan, Gareth J.
PLOS MEDICINE, 2021, 18 (09)
[4] Total Theraphy (TT) for newly diagnosed multiple myeloma (MM): The Arkansas experience with 1000 patients treated on TT1, 2, 3
Barlogie, B
Rasmussen, E
Shaughnessy, J
Anaissie, E
Fassas, A
Talamo, G
Zangari, M
Lee, CK
Thertulien, R
Van Rhee, F
Hollmig, K
Krishna, S
Kiwan, E
Cottler-Fox, M
Crowley, J
Tricot, G
CANCER TREATMENT REVIEWS, 2005, 31 : S12 - S13
[5] Bone marrow morphology (BMM) adds critical prognostic information to other standard parameters (SP) including cytogenetics among newly diagnosed multiple myeloma (MM) patients (PTS) receiving total therapy (TT)
Waldron, J
Jazieh, R
Jagannath, S
Desikan, KR
Siegel, D
Fassas, A
Singhal, S
Mehta, J
Tricot, G
Vesole, D
Wilson, C
Hough, A
Naucke, S
Spoon, D
Barlogie, B
BLOOD, 1997, 90 (10) : 394 - 394
[6] Lack of prognostic implications of induction response to total therapy 2 (TT-2) in newly diagnosed patients with multiple myeloma (MM) for post-transplant even-free survival (EFS) and overall survival (OS).
Tricot, G
Crowley, J
Stover, J
Milner, T
Fassas, A
Zangari, M
Thertulien, R
Anaissie, E
van Rhee, F
Talamo, G
Hollmig, K
Barlogie, B
BLOOD, 2004, 104 (11) : 268A - 268A
[7] Total therapy 2 (No thalidomide arm, TT2-) is superior to total therapy 1 (TT1) for newly diagnosed multiple myeloma (MM): Doubling 4-yr survival among patients with cytogenetic abnormalities (CA) due to consolidation chemotherapy (CCT) and DEX maintenance.
Barlogie, B
Tricot, G
Rasmussen, E
Anaissie, E
van Rhee, F
Zangari, M
Hollmig, K
Milner, T
Epstein, J
Shaughnessy, J
Crowley, J
BLOOD, 2005, 106 (11) : 336A - 336A
[8] Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents
Terpos, Evangelos
Anargyrou, Konstantinos
Katodritou, Eirini
Kastritis, Efstathios
Papatheodorou, Athanasios
Christoulas, Dimitrios
Pouli, Anastasia
Michalis, Eurydiki
Delimpasi, Sosana
Gkotzamanidou, Maria
Nikitas, Nikitas
Koumoustiotis, Vasilios
Margaritis, Dimitrios
Tsionos, Konstantinos
Stefanoudaki, Ekaterini
Meletis, John
Zervas, Konstantinos
Dimopoulos, Meletios A.
INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (03) : 735 - 742
[9] Serum free-lite chain (sFLC) assay in multiple myeloma (MM): Clinical correlates and prognostic implications in newly diagnosed MM patients treated with total therapy 2 or 3 (TT2/3).
Cavallo, F
Rasmussen, E
Zangari, M
Tricot, G
Fender, B
Fox, M
Burns, M
Barlogie, B
BLOOD, 2005, 106 (11) : 974A - 974A
[10] Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Allan, John N.
Roboz, Gail J.
Feldman, Eric J.
Scandura, Joseph M.
Ritchie, Ellen K.
Lam, Linda
Xie, Wen
Hsu, Hsiao-Ting
Hassane, Duane C.
Guzman, Monica L.
BLOOD, 2014, 124 (21)

← 1 2 →